DOI: 10.1093/cid/ciaf147 ISSN: 1058-4838
Glucocorticoids, Concomitant Immunosuppression, and PJP Prophylaxis Among U.S. Adults
Daniel B Chastain, George R Thompson, Andrés F Henao-MartínezAbstract
The impact of glucocorticoids, comorbidities, and immunosuppressive therapies on Pneumocystis jirovecii pneumonia (PJP) risk remains understudied, and prophylaxis is underutilized. Among U.S. adults in TriNetX prescribed glucocorticoids for ≥2 weeks in TriNetX, 44.6% received >20mg prednisone equivalents/day. Prophylaxis rates were low, with higher glucocorticoid doses associated with lower prophylaxis odds.